Trials / Completed
CompletedNCT02210559
A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer
A Randomized, Open Label, Phase 1/2 Trial of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 as Neoadjuvant Chemotherapy in Locally Advanced, Unresectable Pancreatic Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Kyntra Bio · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1/2 trial to evaluate the safety, tolerability, and efficacy of FG-3019 administered with gemcitabine and nab-paclitaxel in the treatment of locally advanced, unresectable pancreatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FG-3019 | FG-3019 will be administered per dose and schedule specified in the arm group description. |
| DRUG | Gemcitabine | Gemcitabine will be administered per dose and schedule specified in the arm group description. |
| DRUG | Nab-paclitaxel | Nab-paclitaxel will be administered per dose and schedule specified in the arm group description. |
Timeline
- Start date
- 2014-07-31
- Primary completion
- 2021-12-15
- Completion
- 2021-12-15
- First posted
- 2014-08-06
- Last updated
- 2023-03-02
- Results posted
- 2023-03-02
Locations
8 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02210559. Inclusion in this directory is not an endorsement.